Good
Mostly Aligned
Patient Risk:
Low
Summary
Partially aligned: the claims about apixaban being the active ingredient and that Eliquis contains apixaban are consistent with provided label context (ELIQUIS apixaban). However, the provided FDA label excerpts do not contain any content supporting the “go generic”/FDA generic-approval timing/patent-exclusivity date claims, so those parts are unsupported by the supplied prescribing information. No label support was provided for DOAC classification language either.
Category Scores
Accurate Statements
Apixaban is the active ingredient in Eliquis.
Supported implicitly by the supplied label context identifying ELIQUIS as apixaban (e.g., FDA label headings and section text refer to ELIQUIS and apixaban interchangeably).
Apixaban is a direct oral anticoagulant (DOAC).
No explicit DOAC terminology was present in the supplied label excerpts; support is therefore not verifiable from the provided text.
Unsupported Statements
The specific "go generic" date for apixaban depends on which patent or exclusivity barrier is the last one preventing an authorized generic or generic approval in a given country.
No generic-market authorization/patent-exclusivity timing statements are present in the provided prescribing information excerpts.
In the US, "going generic" refers to the point when the FDA can approve a generic (or authorized) version of Eliquis that is allowed to be marketed.
The provided label sections do not describe FDA generic approval concepts or any definition of "going generic."
In the US, FDA generic approval timing for apixaban is driven by patent protection and FDA exclusivity status rather than a single universal calendar date.
No statements about patent protection, FDA exclusivity status, or generic approval timing appear in the supplied prescribing information excerpts.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The unsupported claims concern generic-approval timing/market access rather than dosing, contraindications, warnings, or patient-specific safety content in the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims about “go generic”/FDA generic approval timing are not supported by the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Limit the response to label-supported facts (e.g., that ELIQUIS contains apixaban) and remove or clearly source/gate any discussion of patent/exclusivity and generic/authorized-generic approval timing, since it is not present in the supplied label text.